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Introduction
The NLRP12 related autoinflammatory disorder (NLRP12-
RD) is a rare autosomal dominant disease, caused by muta-
tions in the NLRP12 gene, a member of NLRs family involved
in negative regulation of NF-kB pro-inflammatory pathways.
At present, few cases have been reported, although novel
NLRP12 variants have recently been described.
Objective
To assess ex vivo the production of inflammatory cyto-
kines, in patients carrying different NLRP12 variants not
yet demonstrated as being associated to NLRP12-RD, in
order to demonstrate the potential functional and patho-
genic role of these variants.
Materials and methods
30 children, carrying NLRP12 variants in heterozygosis,
and 1 patient, carrying the F402L variant in homozygosis,
were identified using Next Generation Sequencing [G39V
(n=16), F402L (n=8), H304Y (n=3), T260M (n=2) and
G448A (n=1)]; clinical information was collected for all
patients. Patients with G39V were excluded from subse-
quent analysis, due to its high frequency both in our cohort
(17.4%) as in the general population. Whole blood cultures
from NLRP12 patients and Juvenile Idiopathic Arthritis
(JIA) patients (n=10, pathological control) were stimulated
ex vivo with TLRs ligands (LPS 1-10-100 ng/mL, Zymosan
10 μg/mL), with or without the further addition of ATP,
for 5 or 22 hours. TNF-a, IL-1b and IL-6 were measured
in supernatants by ELISA.
Results
Among all stimuli used, we observed a clear inflamma-
tory response in cells stimulated with 10mg/ml of
Zymosan. Indeed, we found that the TNF-a release,
after stimulation with Zymosan, was higherboth at 5
and 22 hours of incubationin all NLRP12 patients,
although carrying different variants, compared to JIA
patients. Moreover, we observed a trend for higher IL-6
levels released from a significant number of NLRP12
patients both at 5 and 22 hours of incubation. Interest-
ingly, we did not find differences in the IL-1b levels
measured in media from NLRP12 patients, compared
with JIA patients. When we investigated parents, carry-
ing the same NLRP12 variant, we did not find any dif-
ferences in cytokines released in response to stimulation
with TLRs ligands, compared with those obtained from
age-matched healthy donors. Moreover, no association
of a specific clinical phenotype with different NLRP12
variants, and a particularcytokine release signature was
observed.
Conclusion
We were not able to demonstrate a clear association of
the investigated NLRP12 variants with the specific clini-
cal phenotype or with the profile of pro-inflammatory
cytokine released ex vivo. Other studies are needed before
final conclusions on the pathogenic role of these NLRP12
variants can be drawn.
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